Research News
Antibody against RSV helps prevent wheeze in infants
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3089 (Published 15 May 2013) Cite this as: BMJ 2013;346:f3089
OpenUrlCrossRefPubMedWeb of Science
Palivizumab is a monoclonal antibody directed against respiratory syncytial virus (RSV) and an effective prophylactic against severe infection in high risk infants. A new trial in preterm infants reports that the drug also helps prevent …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.